News | Mammography | June 23, 2017

Therapixel Wins the Digital Mammography Challenge

Competition encourages development of artificial intelligence algorithms to enhance mammography screening

Therapixel Wins the Digital Mammography Challenge. Marilyn Fornell

June 23, 2017 — French radiology technology company Therapixel was recently named the winner of the Digital Mammography Challenge for their artificial intelligence algorithm designed to enhance mammography reading.

Breast cancer affects one in eight women during their lifetime. Early detection is effective in controlling the disease, with a five-year survival rate greater than 99 percent. However, systematic screening leads to the recall of 10 percent of patients for a complementary biopsy examination. Only 5 percent of the recalled patients are actually affected by the disease.

The Digital Mammography Challenge aims, in the form of a global competition, to improve the performance of screening by exploiting artificial intelligence algorithms. The 2017 Challenge featured more than 1,200 participants and 640,000 anonymous exams. Entries were judged across four rounds over nine months.  

Therapixel’s winning algorithm improves the rate of false positives by 5 percent compared to the state of the art, according to the company.
For more information: www.therapixel.com

Related Content

Imaging Artificial Intelligence (AI) provider Qure.ai announced its first US FDA 510(k) clearance for its head CT scan product qER. The US Food and Drug Administration's decision covers four critical abnormalities identified by Qure.ai's emergency room product.
News | Artificial Intelligence | June 30, 2020
June 30, 2020 — Imaging Artificial Intelligence (AI) provider Qure.ai announced its first US FDA 510(k) clearance for
In new QuickPoLL survey on imaging during the pandemic, responses were tallied from around 170 radiology administrators and business managers, who are part of an imagePRO panel created by The MarkeTech Group (TMTG), regarding the effects of COVID-19 on their business. TMTG is a research firm specializing in the medical device, healthcare and pharmaceutical industries.
Feature | Coronavirus (COVID-19) | June 30, 2020 | By Melinda Taschetta-Millane
Universal digital operating system for surgery enables health tech companies and start-ups to accelerate, scale and grow

Stefan Vilsmeier, President and CEO of Brainlab Photo courtesy of Brainlab

News | Artificial Intelligence | June 26, 2020
June 26, 2020 — ...
QuEST Global, a global product engineering and lifecycle services company, announced that it has developed a robust artificial intelligence (AI)-powered solution that will enable healthcare professionals to accelerate the screening of COVID-19 patients with pneumonia symptoms.

Getty Images

News | Coronavirus (COVID-19) | June 18, 2020
June 18, 2020 — QuEST Global, a global product engineering and lifecycle services company, announced that it has deve
RapidAI acquires comprehensive aneurysm management innovator and expands scope to include aneurysm, extending its leadership in cerebrovascular imaging
News | Artificial Intelligence | June 12, 2020
June 12, 2020 — RapidAI announced the acquisition of
Clinicians can access DLCExpert online (DLCOnline) to help them manage the backlog of cases which has built up during the crisis
News | Artificial Intelligence | June 09, 2020
June 9, 2020 — Mirada Medical, a global leader in...